24 September 2024
Kirkland Advises RLS Radiopharmacies on Sale to Telix
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Jonathan Davis Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| Joseph Raymond Casey Lead | Kirkland & Ellis | Partner | corporate | Not stated |
| Zahraa Hadi | Kirkland & Ellis | Associate | corporate | Not stated |
| Connor O'Flaherty | Kirkland & Ellis | Associate | corporate | Not stated |
| Sara Zablotney | Kirkland & Ellis | Partner | tax | Not stated |
| Mike Conroy | Kirkland & Ellis | Partner | tax | Not stated |
| Drew Stuyvenberg | Kirkland & Ellis | Partner | energy regulatory | Not stated |
| Anthony Del Rio | Kirkland & Ellis | Partner | healthcare | Not stated |
| Micah Desaire | Kirkland & Ellis | Associate | healthcare | Not stated |
| Giselle Lai | Kirkland & Ellis | Associate | healthcare | Not stated |
| Stephen Brecher | Kirkland & Ellis | Partner | executive compensation | Not stated |
| Jeffrey Quinn | Kirkland & Ellis | Partner | employee benefits | Not stated |
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- RLS RadiopharmaciesSell-side
- Counterparties
- Telix Pharmaceuticals Limited (Buy-side)